These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
365 related articles for article (PubMed ID: 35251043)
1. Steroid-Refractory Gut Graft-Versus-Host Disease: What We Have Learned From Basic Immunology and Experimental Mouse Model. Song Q; Nasri U; Zeng D Front Immunol; 2022; 13():844271. PubMed ID: 35251043 [TBL] [Abstract][Full Text] [Related]
2. Bowel wall thickness is a strong predictor of steroid-refractory acute graft-versus-host disease with gut involvement after allo-HSCT. Drokov M; Yatsyk G; Kireeva A; Pirikova O; Dubnyak D; Kuzmina L; Vasilyeva V; Popova N; Starikova O; Parovichnikova E; Savchenko V Int J Hematol; 2022 Apr; 115(4):545-552. PubMed ID: 35098481 [TBL] [Abstract][Full Text] [Related]
3. ECP versus ruxolitinib in steroid-refractory acute GVHD - a retrospective study by the EBMT transplant complications working party. Penack O; Peczynski C; Boreland W; Lemaitre J; Afanasyeva K; Kornblit B; Jurado M; Martinez C; Natale A; Pérez-Simón JA; Brunello L; Avenoso D; Klein S; Ozkurt ZN; Herrera C; Wichert S; Chiusolo P; Gavriilaki E; Basak GW; Schoemans H; Koenecke C; Moiseev I; Peric Z Front Immunol; 2023; 14():1283034. PubMed ID: 38149251 [TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Zeiser R; Burchert A; Lengerke C; Verbeek M; Maas-Bauer K; Metzelder SK; Spoerl S; Ditschkowski M; Ecsedi M; Sockel K; Ayuk F; Ajib S; de Fontbrune FS; Na IK; Penter L; Holtick U; Wolf D; Schuler E; Meyer E; Apostolova P; Bertz H; Marks R; Lübbert M; Wäsch R; Scheid C; Stölzel F; Ordemann R; Bug G; Kobbe G; Negrin R; Brune M; Spyridonidis A; Schmitt-Gräff A; van der Velden W; Huls G; Mielke S; Grigoleit GU; Kuball J; Flynn R; Ihorst G; Du J; Blazar BR; Arnold R; Kröger N; Passweg J; Halter J; Socié G; Beelen D; Peschel C; Neubauer A; Finke J; Duyster J; von Bubnoff N Leukemia; 2015 Oct; 29(10):2062-8. PubMed ID: 26228813 [TBL] [Abstract][Full Text] [Related]
5. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628). von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910 [TBL] [Abstract][Full Text] [Related]
6. [Efficacy of basiliximab in the treatment of 87 cases of steroid-refractory or steroid-dependent acute graft-versus-host disease]. He ZX; Zhang RL; Zhai WH; Ma QL; Pang AM; Yang DL; He Y; Wei JL; Chen X; Jiang EL; Feng SZ; Han MZ Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):120-127. PubMed ID: 35381672 [No Abstract] [Full Text] [Related]
7. Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience. Spałek A; Wieczorkiewicz-Kabut A; Koclęga A; Woźniczka K; Węglarz P; Boral K; Kata D; Zielińska P; Helbig G Int J Hematol; 2022 Dec; 116(6):922-928. PubMed ID: 35972605 [TBL] [Abstract][Full Text] [Related]
8. Ruxolitinib Treatment of Steroid-Refractory Graft-versus-Host Disease in Children: A Case Series and Review of the Literature. Yan WL; Zhao FY; Gu ME; Liu N; Guo XP; Xu XJ Paediatr Drugs; 2023 Sep; 25(5):577-584. PubMed ID: 37284944 [TBL] [Abstract][Full Text] [Related]
9. Vedolizumab in highly resistant acute gastrointestinal graft-versus-host disease after allogeneic stem cell transplantation: A single-center pediatric series. Rosa M; Jarmoliński T; Miśkiewicz-Migoń I; Liszka K; Miśkiewicz-Bujna J; Panasiuk A; Frączkiewicz J; Ussowicz M Adv Clin Exp Med; 2022 Mar; 31(3):345-350. PubMed ID: 35212198 [TBL] [Abstract][Full Text] [Related]
10. Ruxolitinib in steroid refractory graft-vs.-host disease: a case report. Maffini E; Giaccone L; Festuccia M; Brunello L; Buondonno I; Ferrero D; Boccadoro M; Dellacasa C; Busca A; Novero D; Bruno B J Hematol Oncol; 2016 Aug; 9(1):67. PubMed ID: 27502249 [TBL] [Abstract][Full Text] [Related]
11. Clinical Features, Treatment, and Outcome of Pediatric Steroid Refractory Acute Graft-Versus-Host Disease: A Multicenter Study. Verbeek AB; Jansen SA; von Asmuth EGJ; Lankester AC; Bresters D; Bierings M; Mohseny AB; Lindemans CA; Buddingh EP Transplant Cell Ther; 2022 Sep; 28(9):600.e1-600.e9. PubMed ID: 35717003 [TBL] [Abstract][Full Text] [Related]
12. Pathophysiology of gastrointestinal acute graft-versus-host disease and the potential role of glucagon-like peptide 2. Zeiser R; Chen YB; Youssef NN; Ayuk F Br J Haematol; 2023 May; 201(4):620-627. PubMed ID: 36965050 [TBL] [Abstract][Full Text] [Related]
13. Recent advances in acute gastrointestinal graft versus host disease (aGvHD): aspects of steroid-resistant disease. Kujawska J; Zeiser R; Gil L Ann Hematol; 2024 Aug; ():. PubMed ID: 39207560 [TBL] [Abstract][Full Text] [Related]
14. [Anti-CD(25) monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease in 80 patients receiving allogeneic hematopoietic stem cell transplantation]. Tao T; Xue SL; Chen F; Xu Y; Ma X; Miao M; Tang XW; Wu DP Zhonghua Nei Ke Za Zhi; 2018 May; 57(5):324-329. PubMed ID: 29747286 [No Abstract] [Full Text] [Related]
15. Differential protein expression in endothelial cells exposed to serum from patients with acute graft-vs-host disease, depending on steroid response. Martinez-Sanchez J; Palomo M; Pedraza A; Moreno-Castaño AB; Torramade-Moix S; Rovira M; Salas MQ; Cid J; Escolar G; Penack O; Carreras E; Diaz-Ricart M J Cell Mol Med; 2023 May; 27(9):1227-1238. PubMed ID: 37016544 [TBL] [Abstract][Full Text] [Related]
16. Steroid-Sensitive, but Not Steroid-Dependent or Steroid-Resistant Acute Graft-versus-Host Disease, Results in Similar Infection Risk as No Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation. Young JH; El Jurdi N; Rayes A; MacMillan ML; Holtan SG; Cao Q; Witte J; Arora M; Weisdorf DJ Transplant Cell Ther; 2022 Aug; 28(8):509.e1-509.e11. PubMed ID: 35577324 [TBL] [Abstract][Full Text] [Related]
17. Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study. Liu J; Fan Z; Xu N; Ye J; Chen Y; Shao R; Sun Y; Wu Q; Liu Q; Jin H Ann Hematol; 2023 Oct; 102(10):2865-2877. PubMed ID: 37474631 [TBL] [Abstract][Full Text] [Related]
18. C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall Survival after Allogeneic Hematopoietic Stem Cell Transplantation. Minculescu L; Kornblit BT; Friis LS; Schiødt I; Petersen SL; Andersen NS; Sengeloev H Biol Blood Marrow Transplant; 2018 Mar; 24(3):600-607. PubMed ID: 29074374 [TBL] [Abstract][Full Text] [Related]
19. The Potential Roles of Mucosa-Associated Invariant T Cells in the Pathogenesis of Gut Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation. Gao MG; Hong Y; Zhao XY; Pan XA; Sun YQ; Kong J; Wang ZD; Wang FR; Wang JZ; Yan CH; Wang Y; Huang XJ; Zhao XS Front Immunol; 2021; 12():720354. PubMed ID: 34539656 [TBL] [Abstract][Full Text] [Related]
20. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation. Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]